

H1 2017 Results

Conference call and webcast for investors and analysts

27 July 2017



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic competition; the impact of competition, price controls and price reductions; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social media platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.



Presenters



Pascal Soriot
Executive Director and
Chief Executive Officer



Mark Mallon
Executive Vice President,
Global Products & Portfolio
Strategy, Global Medical
Affairs, Corporate Affairs



Jamie Freedman
Executive Vice President and
Head, Oncology Business Unit



Marc Dunoyer
Executive Director and
Chief Financial Officer



Sean Bohan
Executive Vice President,
Global Medicines Development
and Chief Medical Officer



Agenda



Overview



Growth Platforms



Oncology




Finance



Pipeline and news flow



Closing and Q&A



Antibody that blocks inhibitory signals from the tumour to cells of the immune system, resulting in enhanced anti-tumour immunity



Highlights

H1 2017: In line with expectations

Business & financials

Total Revenue declined as anticipated, reflecting mainly the tail impact of *Crestor's* and *Seroquel XR's* US loss of exclusivity

Sales from Growth Platforms increased

- Emerging Markets: Up 6%, some impact from economic conditions in LatAm/MEA¹
 - China: Up 8%; *Tagrisso* off to a strong start
- Respiratory: Continued to be impacted by US *Symbicort*
- New CVMD²: Supported by *Brilinta* (+28%) and *Farxiga* (+22%)
- Japan: Up 6%, supported by lapping of price cuts and strength of *Tagrisso*
- New Oncology: Boosted by *Tagrisso* (\$403m)

EPS growth underpinned by cost management and Other Operating Income

2017 guidance reiterated

1. LatAm/MEA = Latin America and Middle-East & Africa.

2. CVMD = Cardiovascular & Metabolic Diseases.

Growth at Constant Exchange Rates (CER) and for H1 2017, unless otherwise stated. Guidance at CER.



Highlights, continued

Pipeline news summary

Pipeline

Oncology	<ul style="list-style-type: none"> • <i>Imfinzi</i> • <i>Tagrisso</i> • <i>Faslodex</i> • <i>Lynparza</i> 	bladder cancer lung cancer Stage III lung cancer 1L lung cancer 1L breast cancer 1L ovarian cancer 2L	Approval (US) Phase III PACIFIC: Met PFS ¹ primary endpoint Phase III MYSTIC: Did not meet PFS primary endpoint Phase III FLAURA: Met primary endpoint Approval (EU, JP) Regulatory submission acceptance (EU, JP)
Cardiovascular & Metabolic Diseases	<ul style="list-style-type: none"> • <i>Bydureon</i> 	type-2 diabetes CVOT ²	Phase III EXSCEL: Met primary safety objective; did not meet primary efficacy objective
Respiratory	<ul style="list-style-type: none"> • <i>Bevespi</i> • <i>tralokinumab</i> 	COPD severe, uncontrolled asthma	Regulatory submission (EU) Phase III STRATOS 1: Did not meet primary endpoint; results now inform STRATOS 2
Other	<ul style="list-style-type: none"> • <i>Kyntheum</i> 	psoriasis	Approval (EU; received by partner)
New scientist joiners IO franchise	<ul style="list-style-type: none"> • Jean-Charles Soria, SVP, Research and Early Development, from Gustave Roussy Cancer Centre • Geoffrey Kim, Head of Oncology Strategic Combinations, from US FDA 		

1. PFS = Progression-free survival.


2. CVOT = Cardiovascular outcomes trial.

Status since the results announcement on 27 April 2017.



Total Revenue: An inflection point approaching


New AstraZeneca emerging visibly from patent losses



Absolute values at CER. Change at CER and for H1 2017, unless otherwise stated.



2017: Becoming a defining year



1. NSCLC = Non-small cell lung cancer.





Lynparza affirmed as the globally-leading PARP inhibitor

Merck collaboration expands potential, in particular for IO combos

- Establishes *Lynparza* as the preferred PARP-inhibitor backbone of future PD-1/PD-L1 combinations
- Accelerates *Lynparza*'s development with the leading PD-1 inhibitor in clinical trials, *Keytruda*
- Financially-attractive total deal value of up to \$8.5bn

Agenda



Overview



Growth Platforms



Oncology




Finance



Pipeline and news flow








Closing and Q&A



Antibody that blocks inhibitory signals from the tumour to cells of the immune system, resulting in enhanced anti-tumour immunity



Growth Platforms: Focus further strengthened

	Q2 2017 \$m	% change	% Total Revenue	H1 2017 \$m	% change	% Total Revenue
Growth Platforms	3,723	1	74	7,295	3	70
 Emerging Markets	1,442	2	-	3,004	6	-
 Respiratory	1,099	(9)	-	2,280	(4)	-
 New CVMD¹	872	3	-	1,670	4	-
 Japan	617	8	-	1,067	6	-
 New Oncology²	301	99	-	537	n/m	-

1. New CVMD comprises *Brilinta* and *Diabetes*.

2. New Oncology comprises *Lynparza*, *Tagrisso*, *Iressa* US and *Imfinzi*.




Absolute values at actual exchange rates. Change at CER.



Emerging Markets

China performing well

Product Sales growth Long-term target: Mid to high single-digit



China continued solidly; Growth Platforms strong



- **Mid to high single-digit growth continues**
 - Some impact of economic conditions in LatAm/MEA¹
 - Underlying growth 3-6% higher when adjusting for partnerships/divestments
- **Oncology +15%:** Legacy medicines, incl. *Faslodex* (+9%), boosted by *Tagrisso* (\$40m) and China launch
- **New CVMD +23%:** Principal medicines *Brilinta* (+36%) and *Forxiga* (+83%) supporting growth
- **Respiratory +9%:** Continued double-digit growth for important medicine *Pulmicort* (+19%; 60% of total)

1. LatAm/MEA = Latin America and Middle-East & Africa.
Change at CER and for H1 2017, unless otherwise stated.



Respiratory

Continued challenging market for *Symbicort*



Global focus: Emphasis on *Symbicort's* superior profile

US -17%

- Pricing pressure continued as expected
- *Bevespi* off to a solid start

Europe -5%

- Overall stable business volumes
- *Duaklir* (+29%) continues its rollout

Emerging Markets +9%

- *Pulmicort* (+19%)

Absolute values at actual exchange rates.
Change at CER and for H1 2017, unless otherwise stated.

1. *Symbicort* vs. salmeterol/fluticasone+SABA.
Source: QuintilesIMS.




Bevespi in the US

Good, but early path



BEVESPI
AEROSPHERE®

(glycopyrrolate 9 mcg/formoterol fumarate 4.8 mcg)
Inhalation Aerosol



Maximise bronchodilation²

Achieved a 381mL improvement in peak inspiratory capacity



Bevespi is indicated for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

1. NBRx = New-to-brand prescriptions.


2. Improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials.

Source: QuintilesIMS.


New CVMD

Sharper focus on *Brilinta* and *Farxiga*

Brilinta: Strong execution; US NBRx continued to grow



Diabetes: *Farxiga* growth drives global market leadership



Commercial focus sharpened on differentiated medicines

Brilinta

- Continued solid growth in all geographies

Farxiga

- US (-1%)
Impacted by affordability programmes. Sharpened message on HbA1c. Scientific rollout of CVD-REAL study
- Ex-US (55% of total)
Continued growth, e.g. Europe (+24%)




Absolute values at actual exchange rates.
Change at CER and for H1 2017, unless otherwise stated.
Source: QuintilesIMS.

Source: QuintilesIMS. Includes *Farxiga* fixed-dose combinations.



Japan

Tagrisso supports business growth



Absolute values at actual exchange rates.
Change at CER and for H1 2017, unless otherwise stated.


Source: QuintilesIMS.



Oncology

Q2 2017: First quarter since 2010 with ~\$1bn in Product Sales

Oncology Product Sales
New medicines boosting growth



- **Total Oncology**

- **20% growth and 19% of total Product Sales**
- *Faslodex* (+16%) benefited from recent label expansions into 1st-line use and combination

- **New Oncology**


- Commitment to **six new medicines** 2014-2020; three already delivered:
- **Tagrisso**: Very strong uptake, particularly in Asia
- **Imfinzi**: Strategic launch May 2017
- **Lynparza**: Continued strong news flow; 2nd-line ovarian and breast cancer



Tagrisso

Strong growth


Continued global growth



Global commercial execution

- US: T790M¹-mutation testing rate holding back access to *Tagrisso*
 - Progress being made on improving testing and education around ctDNA/plasma retesting
- Europe: More reimbursements secured
- Japan: Continued strong growth; T790M testing rate >90%
- China: First launch in May

1st-line opportunity as seen in EGFRm² cohort from Phase I



Absolute values at actual exchange rates.

1. T790M = Mutation that results in an amino acid substitution at position 790 in EGFR, from threonine (T) to methionine (M).

2. EGFRm = Epidermal growth factor receptor mutation. Source: ELCC 2016, abstract LBA1_PR.



Strategic US launch in bladder cancer; preparing for lung cancer

Bladder cancer US launch

8

Weeks since launch

2nd

'Share of Voice' position

>35%

'Share of Voice' share



Stage III unresectable NSCLC PACIFIC trial

- Met PFS primary endpoint based on interim analysis - trial continues to assess OS¹ primary endpoint, anticipated in 2019 at the latest
- Regulatory submission anticipated in H2 2017
- ~100,000 Stage III patients in G7; about half have unresectable tumours
- Two-three years ahead of competitors

1. OS = Overall survival.


Source: BrandImpact market research, May 2017, AstraZeneca epidemiology data. G7 countries include the US, Japan, Germany, the UK, France, Italy and Canada.




Lynparza

Global leader

US to benefit from ovarian 2L and breast-cancer indication



Significant news flow expected




Absolute values at actual exchange rates.




Lynparza - Merck collaboration

Establish as the preferred PARP-inhibitor backbone of future PD-1/PD-L1 and DNA Damage Response (DDR) combinations



Illustrative




Source: AstraZeneca epidemiology data.
HRRm = Homologous recombination repair mutation.

Lynparza - Merck collaboration

Accelerates development with the leading PD-1 in clinical trials

Ongoing trials for approved PD-1/L1 medicines



Combined more than half of all ongoing trials



Lynparza - Merck collaboration

Summary



Combines capabilities of two main oncology players



Establishes *Lynparza* as the preferred PARP-inhibitor backbone of future PD-1/PD-L1 combinations



Accelerates *Lynparza's* development with the leading PD-1 inhibitor in clinical trials, *Keytruda*



Maximises potential number of treatment options available



Total payments to AstraZeneca of up to \$8.5bn



Agenda



Overview



Growth Platforms



Oncology




Finance



Pipeline and news flow



Closing and Q&A



Antibody that blocks inhibitory signals from the tumour to cells of the immune system, resulting in enhanced anti-tumour immunity



Reported Profit & Loss

	H1 2017 \$m	% change	% Total Revenue	Q2 2017 \$m	% change	% Total Revenue
Total Revenue	10,456	(9)	100	5,051	(8)	100
- Product Sales	9,783	(10)	94	4,940	(8)	98
- Externalisation Revenue	673	(1)	6	111	(15)	2
Gross Margin	81.5%	(1)	-	80.8%	-	-
R&D Expenses	2,802	(1)	27	1,349	(4)	27
SG&A Expenses	4,658	(15)	45	2,358	(20)	47
Other Operating Income and Expense	839	101	8	603	65	12
Tax Rate	11%	-	-	9%	-	-
EPS	\$0.80	41		\$0.38	n/m	

Absolute values at actual exchange rates. Change at CER and for H1 2017, unless otherwise stated.
Gross Margin reflects Gross Profit derived from Product Sales, divided by Product Sales.



Core Profit & Loss

Opex reduction larger than anticipated for FY 2017


	H1 2017 \$m	% change	% Total Revenue	Q2 2017 \$m	% change	% Total Revenue
Total Revenue	10,456	(9)	100	5,051	(8)	100
- Product Sales	9,783	(10)	94	4,940	(8)	98
- Externalisation Revenue	673	(1)	6	111	(15)	2
Gross Margin	83.0%	-	-	82.3%	1	-
R&D Expenses	2,617	(4)	25	1,279	(4)	25
SG&A Expenses	3,728	(9)	36	1,899	(7)	38
Other Operating Income and Expense	958	n/m	9	625	61	12
Tax Rate	19%	-	-	20%	-	-
EPS	\$1.86	1		\$0.87	6	

Absolute values at actual exchange rates. Change at CER and for H1 2017, unless otherwise stated.
Gross Margin reflects Gross Profit derived from Product Sales, divided by Product Sales.




Continued progress and focus on cost discipline

Reduction in Core R&D costs



Significant reduction in Core SG&A costs




Continued reduction in Core costs

- Reduction in Core R&D costs
 - H1 2017: Down by 4%
 - FY 2017: Core R&D costs are expected to be broadly in line with those in FY 2016
- Significant reduction in Core SG&A costs
 - H1 2017: Down by 9%
 - FY 2017: Reduction in FY 2017 not expected to be as large as in H1 2017



Core Operating Profit margin underpinned by news flow



Core Operating Profit margin supported by Core gross margin and reduced expenses

- Core **Gross Margin** strategically supported over time, by the growing influence of speciality-care medicines
- Core **R&D** costs not targeted as a ratio to Product Sales, but driven by opportunities in the late-stage pipeline
- Core **SG&A** costs have the capacity to reduce as momentum in cost discipline continues

Operating leverage expected after return to growth while still retaining flexibility on attractive pipeline opportunities



FY 2017 guidance and capital-allocation priorities

Guidance	
Total Revenue Low to mid single-digit percentage decline	Core EPS Low to mid teens percentage decline

Capital-allocation priorities
Investment in the business
Progressive dividend policy
Strong, investment-grade credit rating
Immediately earnings-accretive, value-enhancing opportunities



Agenda



Overview



Growth Platforms



Oncology




Finance



Pipeline and news flow



Closing and Q&A



Antibody that blocks inhibitory signals from the tumour to cells of the immune system, resulting in enhanced anti-tumour immunity



Q2 2017 late-stage pipeline update

Oncology

- **Imfinzi**
 - bladder cancer: Approval (US)
 - lung cancer: Stage III (PACIFIC): Met PFS primary endpoint
1L (MYSTIC): Did not meet PFS primary endpoint for combo with treme
- **Tagrisso** - lung cancer 1L (FLAURA): Met primary endpoint
- **Faslodex** - breast cancer 1L: Approval (EU, JP)
- **Lynparza** - ovarian cancer 2L: Regulatory submission acceptance (EU, JP)

Cardiovascular & Metabolic Diseases

- **Bydureon** - type-2 diabetes: Met primary safety objective in CVOT; did not meet primary efficacy objective



Respiratory

- **Bevespi** - COPD: Regulatory submission acceptance (EU)
- **tralokinumab** - severe, uncontrolled asthma: Did not meet primary endpoint in first Phase III trial, STRATOS 1

Other

- **Kyntheum** (brodalumab) - psoriasis: Approval (EU, received by partner)




Oncology: Highlights from ASCO 2017 Annual Meeting

100 abstracts; broad presence with *Lynparza*, *Tagrisso* & *Imfinzi*

1

DNA Damage Response


Lynparza OlympiAD Phase III trial in BRCA-mutated metastatic breast cancer and SOLO-2 trial health-related quality of life in BRCA-mutated, metastatic ovarian cancer



2

Tumour Drivers and Resistance

Tagrisso AURA3 Phase III trial and BLOOM Phase I trial in EGFR and/or T790M mutation-positive non-small cell lung cancer (NSCLC) with leptomeningeal disease or metastases of the central nervous system



3

Immuno-Oncology

Imfinzi Study 1108 Phase I/II updates in metastatic bladder cancer and NSCLC as monotherapy and from other trials as monotherapy and combination therapy in other tumour types



AstraZeneca in non-small cell lung cancer (NSCLC)

Overview of approved medicines and ongoing Phase III trials



Patients with EGFR-mutated tumours

~15-20% of patients, but double in Asia



Patients with no EGFR- or ALK-mutated tumours

~75-80% of patients



= Imfinzi + tremelimumab
 = Imfinzi

Stage/progression of disease



() = First/next data anticipated.
Source: AstraZeneca epidemiology data.



NSCLC: Three major news items

Imfinzi and *Tagrisso* continue to inform

Stage III unresectable (10-15% of NSCLC)

PACIFIC trial

- Met a primary endpoint of statistically-significant and clinically-meaningful improvement in PFS based on interim analysis
- Trial continues to assess OS primary endpoint anticipated in 2019 at the latest
- Regulatory submission H2 2017

Stage IV metastatic (~1/2 of NSCLC)

MYSTIC trial

80-85% EGFR wild type

- Did not meet PFS endpoints for *Imfinzi* and treme combination or *Imfinzi* monotherapy
- Trial continues to assess OS primary endpoints for *Imfinzi* and the *Imfinzi* + treme combination
- Final OS data expected H1 2018

FLAURA trial


15-20% EGFR mutated (double in Asia)

- Met the primary endpoint showing a statistically-significant and clinically-meaningful improvement in PFS
- OS is a secondary endpoint; trial will be followed to greater maturity
- Regulatory submission H2 2017

Increased presence in lung cancer across stages and key segments



Imfinzi: MYSTIC trial has more data to come



	2017	H1 2018
Primary endpoints		
<i>Imfinzi</i> + trema combo PFS in 'expressers'	Mid-2017 X PFS final analysis	
<i>Imfinzi</i> + trema combo OS in 'expressers'	OS interim analyses	OS final analysis
<i>Imfinzi</i> OS in 'expressers'	OS interim analyses	OS final analysis

Imfinzi: Overview of ongoing Phase III trials

Broad development programme in NSCLC patients

	ADJUVANT	PACIFIC	MYSTIC	NEPTUNE	PEARL	POSEIDON	ARCTIC
Trial design	Stage Ib-IIIa Randomised, controlled <i>Imfinzi</i> vs placebo	Stage III unresectable Randomised, controlled <i>Imfinzi</i> vs placebo	Stage IV / 1L EGFR/ALK wt Non-sq / sq ² Randomised, controlled <i>Imfinzi</i> , <i>Imfinzi</i> + treme vs SoC	Stage IV / 1L EGFR/ALK wt Non-sq / sq Randomised, controlled <i>Imfinzi</i> + treme vs SoC	Stage IV / 1L EGFR/ALK wt Non-sq / sq PD-L1 expr. Randomised, controlled <i>Imfinzi</i> vs SoC	Stage IV / 1L EGFR/ALK wt Non-sq / sq Randomised, controlled <i>Imfinzi</i> + SoC, <i>Imfinzi</i> + treme + SoC vs SoC	Stage IV / 3L EGFR/ALK wt Non-sq / sq PD-L1 low Randomised, controlled <i>Imfinzi</i> , treme, <i>Imfinzi</i> + treme vs SoC
Primary endpoint(s)	DFS ¹	PFS OS ✓	PFS OS ✗	OS	PFS OS	PFS	PFS OS
Data readout	2020	PFS ✓ 2019 (final OS)	PFS ✗ H1 2018 (final OS)	H2 2018	2020	2019	H2 2017
Recruitment status	Ongoing	Fully recruited	Fully recruited	Fully recruited	Ongoing	Ongoing	Fully recruited



1. DFS = Disease-free survival.


2. Non-sq / sq = Non-squamous / squamous (histology).



Imfinzi: Expected upcoming news flow

Ongoing Phase III trials across tumour types


 = Imfinzi
 = Imfinzi +/- trem

 = fully recruited

Head & neck cancer,
bladder cancer (UC¹)

EAGLE
2L H&N

KESTREL
1L H&N 

DANUBE
1L bladder 


²


Lung cancer
(NSCLC)

POSEIDON
1L IO-IO-CTx triple

PEARL
1L (Asia)

ARCTIC
3L PD-L1 low/neg. 

MYSTIC
1L (final OS) 

NEPTUNE
1L (final OS) 

ADJUVANT
Adjuvant

H2 2017

H1 2018

H2 2018

2018+


Potential leadership in IO & IO-IO combinations across multiple cancer types

1. Urothelial carcinoma.
2. Global trial excluding China.



Oncology: News flow to intensify

Upcoming key late-stage news events



1. Potential fast-to-market opportunity ahead of randomised, controlled trials.
 Timeline based on H1 2017 Results forthcoming major news flow; the exact location of each box is approximate.
 ■ = Relatively bigger news item ■ = Relatively smaller news item



CVMD: Highlights from medical meetings

Jointly addressing metabolic / cardio / renal risks



- June -

- **Farxiga** - Type-2 diabetes (T2D) CVD-REAL real-world evidence study; additional findings/sub-group analyses
- **Farxiga + Bydureon** - T2D DURATION-8 52 weeks and subgroup data
- **Bydureon** + insulin - T2D DURATION-7: Reduction in HbA1c¹, weight, fasting plasma glucose and post-prandial glucose



EUROPEAN SOCIETY OF CARDIOLOGY®

- August -

- **Brilinta** - CV disease New insights from PEGASUS-TIMI 54 trial in high-risk PMI² patients
- **Farxiga** - T2D CVD-REAL real-world evidence study; additional findings/sub-group analyses
- **ZS-9** - hyperkalaemia Clinical outcomes and healthcare resource use in CHF³ patients



- September -

- **Farxiga** - Type-1 diabetes Phase III DEPICT-1 trial primary results
- **Bydureon** - T2D Full data from the Phase IIIb/IV EXSCEL CVOT
- **ZS-9** - hyperkalaemia Clinical and resource burden of hyperkalaemia in diabetic population

1. HbA1c = Glycated haemoglobin A1c.

2. PMI = Perioperative myocardial infarction.

3. CHF = Chronic heart failure.



Late-stage pipeline news flow in 2017 and 2018

Unlocking and realising the potential of new medicines

	H2 2017	H1 2018	H2 2018
Regulatory decision	<p><i>Faslodex</i> - breast cancer 1L (US) <i>Lynparza</i> - ovarian cancer 2L (US)</p> <p><i>Bydureon</i> - autoinjector (US)</p> <p><i>benralizumab</i> - severe, uncontrolled asthma (US)</p>	<p><i>Lynparza</i> - ovarian cancer 2L (EU, JP) <i>benralizumab</i> - severe, uncontrolled asthma (EU, JP)</p>	<p><i>Bevespi</i> - COPD (EU)</p>
Regulatory submission	<p><i>Lynparza</i> - breast cancer <i>Tagrisso</i> - lung cancer 1L</p> <p><i>Imfinzi</i> - lung cancer (PACIFIC) <i>Imfinzi +/- treme</i> - lung cancer (ARCTIC)</p> <p><i>acalabrutinib</i> - blood cancer (US)¹</p> <p><i>Bydureon</i> - autoinjector (EU)</p>	<p><i>Lynparza</i> - ovarian cancer 1L</p> <p><i>moxetumomab</i> - leukaemia <i>selumetinib</i> - thyroid cancer</p> <p><i>Bevespi</i> - COPD (JP) <i>Duaklir</i> - COPD (US) <i>tralokinumab</i> - severe, uncontrolled asthma</p>	<p><i>Imfinzi + treme</i> - lung cancer (NEPTUNE) <i>Imfinzi +/- treme</i> - lung cancer (MYSTIC) - head & neck cancer (KESTREL, EAGLE) - bladder cancer (DANUBE)</p> <p><i>roxadustat</i> - anaemia (US)</p> <p><i>benralizumab</i> - COPD <i>PT010</i> - COPD (JP)</p>
Key Phase III data readouts	<p><i>Imfinzi +/- treme</i> - lung cancer (ARCTIC)</p> <p><i>moxetumomab</i> - leukaemia</p> <p><i>tralokinumab</i> - severe, uncontrolled asthma</p>	<p><i>Lynparza</i> - ovarian cancer 1L</p> <p><i>Imfinzi +/- treme</i> - lung cancer (MYSTIC) (final OS) - head & neck cancer (KESTREL, EAGLE)</p> <p><i>selumetinib</i> - thyroid cancer</p> <p><i>PT010</i> - COPD</p>	<p><i>Imfinzi + treme</i> - lung cancer (NEPTUNE)</p> <p><i>Imfinzi +/- treme</i> - bladder cancer (DANUBE)</p> <p><i>benralizumab</i> - COPD</p> <p><i>anifrolumab</i> - lupus</p>

1. Potential fast-to-market opportunity ahead of randomised, controlled trials.



Agenda



Overview



Growth Platforms



Oncology




Finance



Pipeline and news flow



Closing and Q&A



Antibody that blocks inhibitory signals from the tumour to cells of the immune system, resulting in enhanced anti-tumour immunity



Pipeline-driven transformation continues

New AstraZeneca steadily emerging during 2017

- **H1 2017 in line with expectations**
 - Financials on track
 - Guidance reiterated
 - Continued busy pipeline news flow
- **12 new potential medicines in Phase III/under registration**
- **Oncology progressing**
 - *Tagrisso*, *Lynparza* ahead of expectations
 - *Imfinzi*: PACIFIC positive; MYSTIC waiting for OS
- **Continued busy pipeline news flow over next nine months**



Q & A



H1 2017 Results

Conference call and webcast for investors and analysts

27 July 2017

